molecular and cellular ENDOCRINOLOGY

Cumulative Index 1984
Volumes 34–38

© 1984, Elsevier Scientific Publishers Ireland, Ltd.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner, Elsevier Scientific Publishers Ireland, Ltd., P.O. Box 85, Limerick (Ireland).

Special regulations for readers in the U.S.A. This journal has been registered with the Copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, SALEM, MA 01970 (U.S.A.). If no code appears in an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1980 may be copied for a per-copy fee of US $2.25, also payable through the Center. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the publisher for such copying.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.

PRINTED IN THE NETHERLANDS

Molecular and Cellular Endocrinology, 38 (1984) 223–226
Elsevier Scientific Publishers Ireland, Ltd.

Subject Index to Volumes 34–38 (1984)

Acid phosphatase, 37, 153
ACTH effects, 36, 43; 37, 61, 115
ACTH receptor ontogeny, 38, 93
ACTH secretion, 35, 183; 37, 145
Adenosine effects, 35, 177
Adenylate cyclase, 34, 1, 67, 221; 35, 55; 37, 247
–, activity, 35, 177
–, adrenal gland, 38, 93
–, inhibition, 36, 201
–, pituitary, 37, 277
–, prostate, 38, 53
Adipocytes, 36, 229
Adipose, stromal cells, 37, 61
–, tissue protein kinase, 36, 67
Adrenal, cells, 38, 21
–, gland, enzymes, 38, 87
Adrenergic agonists, 37, 263
–, receptors, 34, 1
Adrenocortical cell culture, 35, 189
–, cells, 34, 59
Affinity columns, 35, 143
Aldosterone, 34, 59
Amino acid transport, 37, 103
Aminoglutethimide effects, 37, 115
Androgen, antihormones, 36, 3
–, effects, 37, 153; 38, 67, 163; 37, 15
–, oestrogen synergy, 38, 103
–, production, 34, 7
Angiotensin effects, 37, 205
Angiotensin II receptors, 37, 181
Anterior pituitary, 37, 277
–, cell culture, 35, 121, 229; 37, 311
–, cell secretions, 35, 47
–, cells, 37, 73
–, gland, 34, 107
–, membranes, 34, 183
–, receptors, 36, 201
Antiandrogens, 37, 153
Antibodies, prolactin receptors, 34, 191
Anti-Mullerian hormone, purification, 34, 23
Antioestrogen binding, 35, 143
Antioestrogens, 36, 211; 38, 31
Antiproliferation, 35, 89
Antral follicles, 34, 91
Aromatase regulation, 37, 61
Artificial capillaries, 37, 73
ATPase activity, 34, 169
Autoradiography, luteal slices, 38, 117

B coefficient of viscosity, 35, 41
Bacitracin, 36, 165
Binding, deglycosylated LH, 37, 29
Brain differentiation, 37, 125
Brain mitochondria, 37, 223
Brain peptide, 36, 53
Breast cancer, 36, 3
–, cell line, 36, 211
–, cells, 35, 89
Bromocryptine effects, 34, 127, 137; 35, 159

Calcitonin gene-related peptide, 36, 53
Calcium effects, 34, 153, 183; 35, 65; 36, 17, 175; 37, 41, 133, 181, 359; 38, 197
–, cyclic AMP levels, 34, 17
–, mobilization, 35, 1
–, release, 36, 37
–, steroidogenesis, 34, 17
–, phospholipid-dependent, protein kinases, 34, 107
Calmodulin effects, 34, 183; 35, 65
Cancer, breast cell line, 35, 167
Capillary membrane perfusion, 37, 73
Carbachol effects, 37, 133
Carcinoma cell lines, 37, 205
Cardiac enzymes, 34, 169
Carrier proteins, 34, 83
Cartilage metabolism, 35, 15
Casein content, 34, 145
Casein synthesis, 35, 221
Catecholamine, effects, 37, 61, 245
–, receptors, 35, 229
Cell shape, 37, 319
–, volume effects, 36, 229
Chloride conductance, 36, 37
Cholera toxin, 34, 67
Cholesterol esterase protein, 35, 131
–, placenta, 38, 197
Cholesteryl ester movements, 38, 187
Cholinergic stimulation, 37, 133
Chondrocytes, 35, 15
Chromatin, 36, 11
–, oestrogen receptor binding, 35, 205
Corpora allata, *Manduca sexta*, 37, 349
Corpus luteum, 34, 91
Corticosterone, 34, 59
Cow, lactating, 34, 51
Cyclic AMP, 34, 1, 17, 67; 37, 263
–, assay, 37, 263

Cyclic AMP, (*continued*)
–, dependent protein kinase, 34, 113; 38, 21
–, effects, 35, 159; 36, 79; 37, 103, 285
–, production, 35, 183; 36, 17, 29, 115, 141, 181, 187
–, responses, 36, 43
Cyclic nucleotide analogues, 36, 67
Cyclic nucleotides, 35, 65
Cyclosporine effects, 35, 159
Cytocholasin D effects, 35, 189
Cytolytic effects, 37, 169

Decidua, 37, 83
Deglycosylated LH, 37, 29
Deiodination, 37, 295
Desensitization, 34, 31, 67, 221; 36, 29, 43, 181; 37, 311; 38, 53
–, Sertoli cells, 34, 1
Dexamethasone effects, 36, 107; 37, 197
Diacylglycerol, 34, 107
Dibutyryl cyclic AMP, 34, 67
–, effects, 34, 17
Differentiation, brain, 37, 125
–, granulosa cells, 34, 201
–, thyroid cells, 38, 141
Disulphide bridges, 37, 181
DNA, 36, 11
–, binding, 38, 1
–, cellulose chromatography, 36, 107
–, synthesis, 34, 145; 38, 141
–, –, regulation, 35, 113
Dopamine, effects, 35, 229; 36, 131; 37, 73
–, processing, 37, 319
–, receptors, 36, 201
Down regulation, 37, 245

Ecdysone metabolism, 38, 13
–, synthesis, 37, 285
EGF, 34, 215
–, effects, 36, 79; 37, 103, 205
–, receptors, 34, 113; 37, 205
Electron microscopy, luteal slices, 38, 117
ELISA, 38, 75
Elutriation, luteal cells, 37, 89
Endocytic pathways, 36, 165
Endocytosis, 37, 245
Endoplasmic reticulum, regulation, 37, 15
Enucleation, 36, 11
Enzyme activities, luteal, 34, 99

0303-7207/84/$03.00 © 1984 Elsevier Scientific Publishers Ireland, Ltd.

Enzyme effects on receptors, 35, 107
Epinephrine effects, 36, 29
Essential fatty acids, ovary, 38, 187
Explant culture, 34, 145
Extracellular matrix effects, 37, 319

Fasciculata zone, 34, 59
Fat cell phosphorylation, 38, 205
Fat cells, 36, 123
Fibroblast, cell line, 36, 29
–, growth factor, 36, 79
Forskolin effects, 36, 115, 201; 37, 51
Frog testis, 38, 215
FSH, 34, 39
–, action, 34, 201
–, binding, 35, 41
–, effects, 34, 221; 35, 97; 36, 141
–, receptors, 37, 215
–, secretion, 35, 121

Gastrin release, 37, 133
Gene, expression, 38, 1
–, transfer, 34, 159
GH, affinity columns, 34, 191
–, binding, 34, 51; 35, 25; 38, 75
–, deficient mice, 37, 241
–, effects, 36, 195; 37, 241
–, recombinant, 38, 109
–, release, 37, 277
–, releasing factor effects, 37, 277
Glomerulosa zone, 34, 59
Glucocorticoid, effects, 35, 33; 36, 107; 37, 169, 197; 38, 1
–, receptors, 36, 107; 38, 1
Glucocorticoids, 34, 169
Glucose oxidation, 37, 241
Glucose-6-phosphate dehydrogenase, 38, 103
Glycotransferases, 37, 233
GnRH, agonist effects, 34, 127; 35, 55
–, analogue effects, 35, 107; 38, 215
–, antagonist effects, 34, 137
–, antiserum effects, 34, 127, 137
–, effects, 37, 191
–, receptors, 35, 107; 37, 139
Golgi complex, 35, 25
Golgi system, regulation, 37, 15
Gonadectomy effects, 35, 83
Gonadotrophs, purification, 36, 157
Gonadotropin receptors, 34, 99; 35, 55
Gonadotropin subunits, 35, 83
Granulosa cells, 34, 91; 37, 215
–, cultures, 35, 97; 36, 141
–, differentiation, 37, 51
–, growth, 34, 201
Graves' disease, 34, 215
Growth factors, 35, 159
Growth factors, (*continued*)
–, effects, 36, 79; 38, 141
–, insulin-like, 34, 83
Growth hormone, affinity columns, 34, 191
–, binding, 34, 51; 35, 25, 151
–, effects, 36, 195
–, secretion, 35, 47
Growth plate cartilage, 35, 15
Growth regulation, 34, 113
Guanine nucleotide regulatory protein, 34, 67

Hashimoto's thyroiditis, 34, 215
hCG, 34, 67, 91
–, effects, 34, 31; 35, 75; 37, 159
–, receptors, 34, 201
–, –, down regulation, 38, 39
Hepatoma cells, 36, 59
Hexose transport, 38, 171
Hormone action, 35, 1; 36, 17
Hormone concentration effects, 36, 29
Hormone receptors, 36, 17
hpg mice, 37, 139
HPLC, of peptides, 38, 81
Human cell lines, 36, 3
Hydroxylase, 17a-, activity, 35, 199
Hydroxytamoxifen receptor, 36, 211
Hyperinsulinemia, 38, 131
Hypothyroidism, 38, 87

IGF-I effects, 37, 109
Immature rats, 34, 137
Immunocytochemistry, 36, 11
Induced proteins, 36, 3
Inhibitors, steroidogenesis, 37, 115
Inositol triphosphate, 36, 37
Insect salivary gland, 36, 37
Insects, 37, 349; 38, 13
Insulin, 34, 169
–, binding, 36, 229
–, cross-linked, 36, 165
–, degradation, 36, 229
–, effects, 35, 97; 36, 123; 37, 109; 38 171
–, receptors, 36, 59
–, release, 36, 175
Insulin-like growth factor, 34, 83
Internalization, 34, 39; 35, 25; 36, 229
Interstitial cells, prepubertal, 34, 7
Interstitial fluid factor, 37, 159
Intracellular receptors, 35, 25
Intratesticular regulatory factors, 37, 159
Iodide trapping, 36, 79
Iodination, 36, 95
–, surface, 36, 59
Islet function, 36, 175
Isoenzymes, protein kinases, 38, 21
Isoproterenol, 34, 1
–, effects, 34, 221
Isozymes, 36, 67

Juvenile hormone, 37, 349

Kidney, collecting tubule, 37, 263
–, mouse, 38, 67

Lactation, 35, 113
Lactogenic binding sites, 37, 301
–, receptor, 38, 61
Lactose synthetase, 35, 221
Lactotrophs, 37, 73
LDL receptors, 38, 197
Lectin effects on receptors, 35, 107
Levator ani muscle, 38, 103
Leydig cell, 34, 67
–, hypertrophy, 35, 75
Leydig cells, 34, 7, 17, 31; 36, 115; 37, 29, 159, 331; 38, 39
LH, action, 34, 7
–, effects, 34, 17; 36, 115
–, receptor, down regulation, 38, 39
–, receptors, 34, 91, 201; 36, 187; 37, 51, 215
–, release, 35, 121
–, secretion, 35, 83, 121
–, subunits, 37, 29
LHRH, (*see also* GnRH), 34, 7
–, action, 34, 7
–, agonist action, 34, 7, 17
–, agonist effects, 36, 115
–, effects, 36, 157
Lipases, hormone-insensitive, 35, 131
Lipid droplets, 34, 59
Lipid granules, ovary, 38, 187
Lipogenesis, 37, 241
Lipoprotein deficiency, 34, 59
Lithium effects, 36, 37
Liver, 34, 51
–, development, 36, 195
–, lysosomes, 35, 25
–, membrane binding, 35, 151
–, mitochondria, 37, 223
–, regeneration, 34, 113
Luteal cell sizes, 37, 89
Luteal cells, 36, 187
Luteal slices, 38, 117
Luteolysis, 34, 99
Lyase, C17–20, activity, 35, 199
Lymphoid neoplasia, 36, 107
Lymphoma cell line, 36, 29
Lymphoma cells, 36, 107
Lymphosarcoma P1798 variants, 37, 169
Lysosomes, 36, 165

Macroglobulin a2, 36, 165
Magnesium effects, 38, 179
Mammary cells, 35, 167
Mammary glands, 34, 51, 191; 35, 221
Mammary tissue casein, 34, 145
Manduca sexta, 37, 285
MCF7 cells, 35, 167
Medullary thyroid carcinoma, 36, 53
Methionine oxidation, 38, 81
Methylamine effects, 36, 175
Microtubules, Leydig cells, 38, 39
Microvillous membranes, 38, 197
Monoclonal antibodies, 34, 23
–, GH, 38, 75
Morphology, luteal cells, 37, 89
Mullerian-inhibiting substance, 34, 23
Multiplication-stimulating activity, 34, 83
Myometrium, 35, 177
Myosin ATPase, 34, 169
Myosin isoenzyme distribution, 34, 169

NADPH effects, 36, 95
Neoplastic mammary tissue, 34, 145
Neuropeptide effects, 37, 349
Norepinephrine effects, 35, 229
Nuclear matrix, 36, 11
Nuclease, hypersensitive sites, 35, 205

Oestradiol, effects, 35, 199; 38, 31
–, production, 34, 121
–, receptors, 36, 211
Oestrogen, effects, 34, 153; 35, 113, 167
–, receptors, 35, 89, 205; 36, 195; 38, 151
–, –, model, 36, 11
–, –, protein, 35, 143
Oestrogen–androgen synergy, 38, 103
Oestrous cycle, 34, 99; 35, 113
Ornithine decarboxylase, 35, 159; 38, 67
–, activity, 38, 31
Ovarian follicular maturation, 35, 55
Ovarian steroidogenesis, 34, 121; 35, 199
Ovarian substance effects, 36, 141
Ovaries, insect, 38, 13

Pancreatic tumour, 38, 81
Paracrine regulation, 37, 331
Parathyroid cells, 38, 179
Parous mice, 35, 221
Pectoralis major muscle receptors, 35, 215
Percoll gradients, 37, 331
Periventricular mesencephalon, 36, 53
Peroxidase activity, 36, 95
Peroxide generation, 36, 95
PHI effects, 35, 183
Phosphatidylinositol metabolism, 36, 157
Phosphodiesterase inhibitor effects, 37, 51
Phosphoinositide metabolism, 36, 37
Phosphoinositides, 35, 1
Phospholipase C, 36, 123
Phospholipases, 35, 1
Phospholipid calcium-dependent protein kinases, 34, 107
Phospholipid-sensitive Ca^{2+}-dependent protein kinase, 35, 65
Phospholipids effects, 35, 1
Phosphorylation, endogenous substrates, 35, 65
Photoaffinity labelling, 35, 107; 36, 59
Pituitary adenomas, 37, 145
Pituitary cell cultures, 36, 131
Pituitary cells, 36, 157
Pituitary hormone release, 37, 83
Pituitary membrane receptors, 35, 107
Pituitary peptide, 36, 53
Pituitary testicular function, 34, 127, 137
Pituitary tumour cell growth, 35, 33
Pituitary tumour cell line, 36, 211
Pituitary tumour cells, 35, 183; 37, 41
Pituitary tumours, 36, 221
Placenta, 38, 197
Placental secretion, 37, 359
Plasminogen activators, 35, 157
Plating density effects, 34, 201
Polyamine levels, 38, 31
Polyphosphoinositide metabolism, 36, 37
Pregnancy, 35, 113; 37, 89
Pregnant mare serum, 37, 215
Prelysosomes, 35, 25
Pro-opiomelanocortin peptides, 37, 145
Progesterone effects, 35, 177
–, production, 36, 187
–, receptor, function, 37, 1
–, –, immunology, 37, 1
–, –, structure, 37, 1
–, secretions, 34, 201
Progestin-specific markers, 36, 3
Progestogen, production, 34, 7
Prolactin, binding, 34, 51, 191
–, effects, 35, 113, 159; 36, 187; 38, 53
–, processing, 35, 25
–, receptor, 34, 191; 35, 55; 36, 195; 38, 61
–, release, 36, 221
–, secretion, 35, 47; 35, 229; 36, 131; 36, 201; 37, 41, 359
–, storage sites, 37, 83
Promatostatin, isolation, 38, 81
Prostaglandin E1 effects, 36, 29; 38, 53
Prostaglandin F2a, 34, 99
Prostaglandin internalization, 38, 117
Prostate, 38, 53
Protein deficiency, 37, 301
Protein kinase, 34, 183; 35, 65
–, activity, 36, 59
–, cyclic AMP dependent, 36, 67
Protein kinase, (*continued*)
–, calcium, phospholipid-dependent, 34, 107
Protein phosphorylation, 34, 107, 113, 183; 35, 65; 36, 67; 37, 205; 38, 205
Protein synthesis, 37, 139, 197
Prothoracic hormone effects, 37, 285
PTH release, 38, 179
Pyruvate dehydrogenase, 36, 123

Radioimmunoassay of casein, 34, 145
Rb efflux, 35, 47
Receptor phosphorylation, 34, 113
Receptor-specific mechanisms, 37, 245
Refractoriness, 35, 75; 36, 221
RNA, content, 35, 159
–, polymerase, 37, 223
–, synthesis, 37, 109
mRNA, 34, 169
–, pituitary levels, 35, 83
–, regulation, 37, 15

Salt, monovalent, effects, 35, 41
Secretory vesicles, 37, 83
Seminal vesicle protein synthesis, 38, 163
Seminal vesicles, 37, 15
Seminiferous tubule effects, 37, 331
Serine phosphorylation, 34, 113
Sertoli cell, 34, 1; 37, 159
–, membranes, 34, 221
–, culture, 34, 39
Serum effects, 36, 79
Serum inhibition, 34, 201
Sex difference, 36, 195
Sex differentiation, 34, 23
Sex status, 35, 215
Silk worm, 38, 13
Skeletal muscle, cultures, 38, 171
–, receptors, 35, 215
Sodium effects, 37, 181
Sodium requirements, 35, 47
Soleus muscle, 37, 109
Somatogenic, binding sites, 37, 301
–, receptor, 38, 61
Somatomedin, 34, 83
Somatomedin-C levels, 37, 301
Somatostatin effects, 37, 277, 311
Somatotropin radioreceptor assay, 38, 109
Steroid production, 35, 189
Steroid-responsive genes, 34, 159
Steroidogenesis, 34, 59; 38, 93
–, adrenal cells, 36, 43
–, adrenal gland, 35, 131; 37, 115
–, granulosa cells, 35, 97; 37, 51
–, insects, 37, 285
–, Leydig cells, 37, 29
–, luteal cells, 36, 187
–, ovary, 36, 141
Stress fibre organization, 35, 189

Succinate cytochrome C reductase, 37, 223
Sulphydryl group, 38, 61
Superfused adrenal cells, 36, 43
Superfusion, pituitary, 37, 145

Tamoxifen, 36, 211
–, effects, 35, 89
Testis, 34, 7, 31; 35, 41
–, foetal, 34, 23
–, foetal and neonatal, 37, 191
Testosterone, effects, 34, 121; 37, 15
–, metabolism, 35, 15
–, production, 37, 331; 38, 215
–, –, biphasic, 35, 75
–, secretion, 37, 159, 191
Thecal steroidogenesis, 34, 91
–, tissue, 34, 91
Thioridazine, 34, 183
Thymidine incorporation, 34, 215; 35, 33
Thyroid autoantibodies, 34, 215
Thyroid cell, culture, 37, 233, 257; 36, 181; 38, 141
Thyroid cell, (*continued*)
–, differentiation, 36, 79
–, proliferation, 36, 79
Thyroid cellular growth, 34, 215
Thyroid follicles, 34, 215
Thyroid hormone analogues, 37, 223
Thyroid hormone effects, 37, 125; 38, 87, 205
Thyroid hormones, 34, 169; 37, 295
Thyroid peptide, 36, 53
Thyroid peroxidase, 36, 95
Thyroid tissue, 37, 295
Thyrotrophs, 37, 73
Thyrotropin effects, 36, 79
Tosylarginine methyl ester hydrolase, 34, 153
Transglutaminase, 35, 159; 36, 175
Transvection, 34, 159
TRH effects, 36, 131, 221; 37, 73
Triacylglycerol lipase protein, 35, 131
Trifluoroperazine, 34, 183
Triiodothyronine nuclear receptors, 35, 215
Trilostane effects, 37, 115
Trophoblast secretion, 37, 359
TSH, 38, 141
–, effects, 36, 79, 181; 37, 233, 257
–, receptors, 37, 337
Two-dimensional electrophoresis, 37, 197
Type II protein kinase, 36, 67
Tyrosine aminotransferase, 36, 165
Tyrosine hydroxylase induction, 38, 87
Tyrosine phosphorylation, 34, 113

Ultra structure, 34, 59
Uterine growth, 38, 31
Uterine protein, 35, 143
Uterus, immature, 34, 153

Vasopressin, effects, 37, 263
–, receptor, 38, 131
Ventral prostate, 37, 153
VIP effects, 36, 221; 37, 41
Vitellogenin gene transcription, 38, 151

Xenopus hepatocyte cultures, 38, 151

Molecular and Cellular Endocrinology, 38 (1984) 227–229
Elsevier Scientific Publishers Ireland, Ltd.

Author Index to Volumes 34–38 (1984)

Abrahams, P., 37, 153
Adamafio, N.A., 37, 241
Aguilera, G., 37, 277
Alsat, E., 38, 197
Andersen, T.T., 35, 41
Asgeirsson, B., 34, 183
Ashcroft, S.J.H., 34, 107
Ashkenazi, A., 34, 51
Attramadal, H., 34, 1, 221

Bachrach, L.K., 38, 141
Bacou, F., 35, 215
Balkow, C., 35, 131
Bambara, R.A., 35, 205
Barber, R., 36, 29
Bardon, S., 35, 89
Barzilai, D., 37, 359
Bata, J., 38, 21
Baukal, A.J., 35, 55
Baulieu, E.-E., 35, 177
Beebe, S.J., 36, 67
Belkhiria, M., 37, 223
Ben-Jonathan, N., 35, 229
Berkowitz, A.S., 35, 121
Berridge, M.J., 36, 37
Berthelier, M., 38, 197
Bethea, C.L., 37, 319
Bick, T., 37, 359
Bicknell, R.J., 35, 47
Birabeau, M.A., 37, 181
Bird, C., 37, 153
Bjoro, T., 37, 41
Bok, S., 35, 15
Bolander, Jr., F.F., 35, 221
Bollenbacher, W.E., 37, 285, 349
Bouali, Y., 35, 197
Bouchard, P., 35, 177
Bouchilloux, S., 37, 233, 257
Boye, N., 37, 295
Brandle, W., 34, 67
Bressot, C., 35, 215
Brown, C.M., 37, 133
Brown, E.M., 38, 179
Buchan, P.B., 36, 37
Bullock, L.P., 38, 67
Burdman, J.A., 35, 113
Burrow, G.N., 38, 141
Butcher, R.W., 36, 29

Cailleau, J., 34, 7
Calvo, J.C., 34, 31
Canonico, P.L., 36, 221
Cantau, B., 38, 131
Capony, F., 35, 167
Capponi, A.M., 37, 181
Cardon, S.B., 35, 159
Caron, M.G., 36, 201
Carrascosa, A., 35, 15
Cathiard, A.M., 38, 93
Catt, K.J., 35, 55
Cedard, L., 38, 197
Chabardes, D., 37, 263
Chalbos, D., 36, 3
Champion, J., 38, 151
Channabasavaiah, K., 34, 127, 137
Charlton, H.M., 37, 139
Charreau, E.H., 34, 31; 36, 187
Chegini, N., 37, 89; 38, 117
Cheng, C.H.K., 38, 61
Chevillard, C., 38, 131
Chiauzzi, V.A., 36, 187
Chieffi, G., 38, 215
Chvatchko, Y., 36, 59
Clark, A., 37, 153
Clayton, R.N., 34, 127, 137; 37, 61, 139
Cleland, W.H., 37, 61
Cobbs, G., 38, 117
Cohen, M.F., 38, 141
Collier, R.J., 38, 109
Conlon, J.M., 38, 81
Conn, P.M., 37, 83
Cooke, B.A., 34, 17; 36, 115
Cooper, I., 37, 159
Copeland, J.G., 35, 159
Corbani, M., 35, 83
Corbin, J.D., 36, 67
Corcelle-Cerf, F., 37, 115
Correze, C., 38, 205
Corvol, M.T., 35, 15
Costa, N.D., 38, 187
Counis, R., 35, 83

Dahlberg, P.A., 34, 215
Dainat, J., 35, 215
Davoren, J.B., 35, 97

de Bruin, T.W.A., 37, 337
De Kretser, D.M., 35, 75; 38, 39
Deis, R.P., 35, 113
Dembri, A., 37, 223
Deme, D., 36, 95
Derocq, D., 35, 89
Detta, A., 37, 139
Deviller, P., 38, 21
Di Matteo, L., 38, 215
Dieguez, C., 37, 73
Dillmann, W.H., 34, 169
Djiane, J., 34, 145; 35, 25
Dumont, J.E., 36, 79
Durand, P., 38, 93

Earp, H.S., 34, 113
Edery, M., 34, 145
Eggo, M.C., 38, 141
Ekre, H.-P.T., 38, 75
Epstein-Almog, R., 36, 141
Errick, J., 38, 141

Farese, R.V., 35, 1
Farkash, Y., 36, 141
Fasano, S., 38, 215
Fawell, S.E., 37, 15
Fayet, G., 37, 233, 257; 38, 141
Fehlmann, M., 36, 59; 37, 103
Ferland, L.H., 35, 25
Filetti, S., 36, 181
Fischer, J.A., 36, 53
Fletcher, P.W., 34, 39
Flint, D.J., 36, 229
Foord, S.M., 37, 73
Franc, J.-L., 37, 223, 257
Fraser, H.M., 34, 127, 137
Fuller, P.J., 37, 197
Funder, J.W., 37, 197

Gamou, S., 37, 205
Garcia, M., 35, 167
Gardner, M.J., 36, 229
Gautvik, K.M., 37, 41; 38, 53
Gavaret, J.M., 38, 205
Gazzano, H., 36, 59

Gehring, U., 36, 107
Gertler, A., 34, 51
Gilbert, L.I., 37, 285
Goka, T.J., 36, 29
Goldring, N.B., 36, 141
Goldstein, S., 38, 197
Gomis, R., 36, 175
Gordeladze, J.O., 38, 53
Gorski, J., 36, 11
Granger, N.A., 37, 349
Grewe, C., 37, 277
Gripois, D., 38, 87
Grotjan Jr., H.E., 35, 121
Guillon, G., 38, 131

Hall, R., 37, 73
Handwerger, S., 37, 83
Hansson, V., 34, 1; 34, 221
Haro, L.S., 38, 109
Harty, R.F., 37, 133
Harwood, J.P., 37, 277
Haug, E., 37, 41
Hazum, E., 35, 107
Heath, D.A., 34, 91
Heiman, M.L., 35, 229
Heisler, S., 35, 183
Henderson, K.M., 34, 91
Herchuelz, A., 36, 175
Hershkovits, N., 36, 141
Hertel, C., 37, 245
Heslop, J.P., 36, 37
Higgins, S.J., 37, 15
Hilf, R., 35, 205
Hochberg, Z., 37, 359
Hodgson, Y.M., 35, 75
Hoefer, M.T., 35, 229
Houben, P.W., 38, 67
Houdebine, L.-M., 34, 145; 35, 25
Hovsepian, S., 37, 233, 257
Hsueh, A.J.W., 35, 97; 37, 51
Huhtaniemi, I., 34, 127, 137; 37, 331
Hung, C.H., 35, 151

Imbert-Teboul, M., 37, 263
Ireland, J.J., 34, 99
Ito, F., 36, 165

0303-7207/84/$03.00 © 1984 Elsevier Scientific Publishers Ireland, Ltd.

Ito, S., 36, 165

Jackson, I.M.D., 37, 73
Jahn, G.A., 35, 113
Jahnsen, T., 34, 221
Janzen, W.P., 37, 349
Jia, X.-C., 37, 51
Johnson, D.C., 35, 199
Jonsdottir, I., 38, 75
Jordan, V.C., 35, 143; 36, 211
Jorgensen, E.C., 37, 223
Josso, N., 34, 23
Judd, A.M., 36, 221
Jutisz, M., 35, 83

Kaniewski, J., 36, 95
Karlsson, F.A., 34, 215
Katoh, M., 34, 191
Katzenellenbogen, B.S., 38, 31
Keel, B.A., 35, 121
Keinan, D., 35, 107
Kelly, P.A., 34, 145, 191; 35, 25
Kendra, K.L., 38, 31
Kerr, J.B., 38, 39
Ketelslegers, J.-M., 37, 301
Khalid, B.A.K., 37, 197
Kieboom, L.E., 34, 91
Kilpatrick, B.F., 36, 201
Kim, Y.S., 37, 205
Knecht, M., 35, 55
Koepfer-Hobelsberger, B., 36, 123
Kolanowski, J., 37, 115
Korhonen, M., 35, 55
Kozak, S.L., 37, 319
Kudlow, J.E., 38, 141
Kunau, W.-H., 35, 131
Kuo, J.F., 35, 65

Labrie, F., 35, 183; 36, 157
Ladenheim, R.G., 36, 187
Lahav, M., 37, 359
Lambert, F., 37, 115
Lammerant, J., 37, 115
Larson, D.F., 35, 159
Laurberg, P., 37, 295
Laws, A.O., 38, 39
Le Gac, F., 34, 1
Le Marchand-Brustel, Y., 37, 109
Leblanc, G., 34, 191
Lebrun, P., 36, 175
Lee, G., 38, 187
Lefevre, G., 36, 157
Leung, P.C.K., 36, 157
Leveque, N.W., 35, 121
Liu, W.-K., 37, 29
Loeb, D., 38, 67
Ludecke, D.K., 37, 145
Lun, S., 34, 91
Luthman, M., 38, 75

MacLeod, R.M., 36, 221
Madar, Z., 34, 51
Maes, M., 37, 301
Maico, D.G., 37, 133
Malaisse, W.J., 36, 175
Malaisse-Lagae, F., 36, 175
Malassine, A., 38, 197
Martin, H., 35, 199
Mason, J.I., 35, 189
Massot, O., 35, 167
Mathieu, M.-N., 38, 131
Max, S., 38, 103
May, J.V., 34, 201
Mazzei, G.J., 35, 65
McCarthy, D.M., 38, 81
McDonald, W.M., 36, 201
McGuigan, J.E., 37, 133
McNatty, K.P., 34, 91
Mendelson, C.R., 37, 61
Mester, J., 37, 1
Michel, O., 37, 223
Michel, R., 37, 223
Michot, J.L., 36, 95
Milewski, M.A., 34, 107
Minucci, S., 38, 215
Mitchell, L.J., 37, 349
Mondon, F., 38, 197
Monier, S., 37, 109
Montegut, M., 37, 263
Moore, W.V., 35, 151
Morel, F., 37, 263
Moudgal, N.R., 37, 215
Mueller, G.C., 35, 143
Mugele, K., 36, 107

Naik, S.I., 37, 139
Naor, Z., 37, 191
Newman, G.R., 37, 73
Ng, F.M., 37, 241
Nichols, N.R., 37, 197
Nikula, H., 37, 331
Norstedt, G., 36, 195
Nunez, J., 37, 125; 38, 205

Ogiso, M., 38, 13
Ohnishi, E., 38, 13
Olsen, M.R., 35, 143
Omri, B., 38, 205
Orly, J., 36, 141

Page, M.J., 34, 159
Parker, M.G., 34, 159
Parvinen, M., 37, 331
Perkins, J.P., 37, 245
Perlman, A.J., 38, 151
Perlman, R., 37, 359
Perlmann, P., 38, 75
Peters, J.R., 37, 73
Picard, J.Y., 34, 23
Pierantoni, R., 38, 215
Pommier, J., 36, 95
Pratt, K., 35, 205
Purvis, K., 38, 53

Rackoff, W.R., 34, 113
Radicella, J.P., 34, 31
Raeside, J.I., 37, 191
Rafferty, B., 36, 43
Rainey, W.E., 35, 189
Ramani, N., 37, 89
Ranta, T., 35, 55
Rao, C.V., 34, 99; 37, 89; 38, 117
Rapoport, B., 36, 181
Rappaport, R., 35, 15
Ray, K.P., 36, 131
Raymond, V., 36, 157
Rayson, B.M., 37, 197
Rebiere, A., 35, 215
Reichert Jr., L.E., 34, 39; 35, 41
Renoir, J.-M., 37, 1
Risdall, J.E., 34, 215
Robinson, D.J., 37, 191
Roche, J.F., 34, 99
Rochefort, H., 35, 89, 167; 36, 3
Roger, P.P., 36, 79
Rorke, E.A., 38, 31
Rousseau, G.G., 38, 1
Rubin, R.A., 34, 113
Rui, H., 38, 53
Russell, D.H., 35, 159

Saez, J.M., 38, 21, 93
Saith, S., 35, 47
Sakai, D., 36, 11
Sand, O., 37, 41
Scanlon, M.F., 37, 73
Schaison, G., 35, 177
Schatzman, R.C., 35, 65
Schofield, J.G., 34, 183; 35, 47
Schomberg, D.W., 34, 201
Schulster, D., 36, 43
Schumacher, M., 34, 67
Schwarz, M., 34, 67
Sener, A., 36, 175
Seto, P., 36, 181
Shanahan, M.F., 38, 171
Sharpe, R.M., 37, 159
Shay, J.W., 35, 189
Shewring, G., 37, 73
Shimizu, N., 36, 165; 37, 205
Shoback, D.M., 38, 179
Shoshani, R., 36, 141
Sibley, D.R., 36, 201
Simpson, E.R., 37, 61
Smith, G.L., 34, 83
Smith, M.A., 37, 311
Smith, M.E., 37, 61
Smith, W.A., 37, 285
Sonnenborn, U., 35, 131
Starzec, A., 35, 83
Stevenson, P.M., 38, 187
Stewart, J.M., 34, 127, 137
Sullivan, M.H.F., 34, 17; 36, 115
Suzuki, K., 34, 121
Svec, F., 35, 33
Szabo, D., 34, 59
Szalay, K.S., 34, 59

Takahashi, Y., 35, 15
Talamantes, F.J., 38, 109
Tamaoki, B., 34, 121
Tata, J.R., 36, 17; 38, 151
Tate, A.C., 35, 143; 36, 211
Tenniswood, M., 37, 153
Tesone, M., 36, 187
Thatcher, J.G., 38, 179
Thomas, G., 35, 177
Thompson Jr., E.A., 37, 169
Tobler, P.H., 36, 53
Toth, I.E., 34, 59
Trzeciak, W.H., 35, 131
Tsagris, L., 35, 15
Tsai-Morris, C.H., 35, 199
Tschopp, F.A., 36, 53
Tsim, K.W.K., 38, 61
Tuckey, R.C., 38, 187
Turgeon, J.L., 34, 107
Turner, R.S., 35, 65

Ulrich, J., 36, 107
Underwood, L.E., 37, 301

Vale, W.W., 37, 311
Valens, M., 38, 87
Vallier, P., 38, 21
Vallotton, M.B., 37, 181
van der Heide, D., 37, 337
Van Obberghen, E., 36, 59
van Oosbree, T.R., 35, 143
Varriale, B., 38, 215
Veilleux, R., 35, 183; 36, 157
Verhoeven, G., 37, 7

Vidal-Chicot, D., 38, 131
Vidyashankar, N., 37, 215
Vigneron, P., 35, 215
Vignon, F., 35, 89
Virion, A., 36, 95
Visciano, G., 37, 103

Wallis, M., 36, 131
Walsh, D.A., 34, 107
Ward, D.N., 37, 29
Waring, D.W., 34, 107
Weinberger, M.J., 38, 163
Weinberger-Ohana, P., 36, 141
Welsh, Jr., T.H., 37, 51
Welshons, W., 36, 11
Westermark, B., 34, 215
Westphal, M., 37, 145
Wieland, O.H., 36, 123
Wierowski, J.V., 35, 205
Williams, B., 36, 43
Wilson, S., 37, 83
Wolffe, A.P., 38, 151
Wood, K.M., 37, 169

Yamamoto, G., 37, 311
Young, J.D., 37, 29
Young, L.S., 37, 139

Molecular and Cellular Endocrinology, 38 (1984) 230
Elsevier Scientific Publishers Ireland, Ltd.

Acknowledgements of Referees 1984

We are grateful to the following people who have refereed manuscripts for this journal during 1984:

AB, G.
Adiga, P.R.
Ahren, K.
Andreasen, P.A.
Ascoli, M.
Ashcroft, S.T.

Baker, B.
Baldwin, S.
Baulieu, E.E.
Beato, M.
Beavo, J.A.
Behrman, H.R.
Bell, P.A.
Berridge, M.J.
Birnbaumer, L.
Bockaert, J.
Boeynaems, J.M.
Bresciani, F.
Brinkman, A.
Brown, K.
Brown, B.L.
Bruckdorfer, R.
Butcher, R.W.

Carpentier, J.H.
Channing, C.P.
Chap, H.
Clayton, R.
Conn, M.
Conti, M.
Cooke, B.A.
Correze, C.
Craig, R.
Cushman, S.W.

de Asua, L.J.
de Jong, F.H.
de Jonge, H.R.
de Kloet, E.R.
de Kretser, D.M.
Dix, C.J.
Djiane, J.
Dorrington, J.H.
Drummond, A.H.
Dufau, M.L.
Dumont, J.E.

Ekholm, R.
Erickson, G.F.
Ericson, L.E.
Evans, W.H.

Fehlmann, M.
Fischer, J.A.
Friesen, H.G.

Gehring, U.
Gill, G.N.
Glossman, H.
Gorski, J.
Groner, B.
Grootegoed, A.
Gschwendt, M.

Hackenthal, E.
Halestrap, A.
Hall, R.
Hall, P.F.
Hanoune, J.
Hansson, V.
Hekkelman, J.
Hennemann, G.
Hers, H.G.
Higgins, S.
Hilgenfeldt, U.
Hillier, S.G.
Hilz, H.
Hoffmann, J.
Hofmann, F.
Hopkins, C.R.
Hornsby, P.
Houslay, M.D.
Hsueh, A.J.W.
Huhtaniemi, I.
Hunter, M.G.
Hutton, J.C.

Iyengar, R.

James, V.H.
Jordan, V.C.
Jutisz, M.

Koolman, J.

Lazdunski, M.
Leake, R.E.
Leung, P.C.
Lissitzky, S.

Malaisse, W.J.
Martin, L.
Mather, J.
Mecke, D.
Meyer, P.
Milgrom, E.
Morel, F.
Mulder, E.

Nahorski, S.R.
Naor, Z.
Nicholson, R.I.
North, W.G.
Numa, S.
Nunez, J.

Oppenheimer, J.H.
Orly, J.

Parker, M.
Pasteels, J.L.
Payne, A.H.
Perkins, J.P.
Pommier, J.
Posner, B.I.
Pratt, G.
Puett, D.J.

Rees Smith, B.
Reichert, Jr, L.E.
Richards, J.
Ritzen, E.M.
Robel, P.
Rochefort, H.
Rommerts, F.F.
Rosen, J.
Rudland, P.S.
Russell, D.H.

Saez, J.M.
Saggerson, E.
Sairam, M.R.
Salomon, Y.
Salzer, M.
Samuels, H.H.
Schimke, R.T.
Schulster, D.
Schultz, G.
Schumacher, M.
Schutz, G.
Schwartz, H.L.
Setchell, B.P.
Sharpe, R.M.
Sheppard, J.R.
Simpson, E.R.
Sonenberg, M.
Stansfield, D.A.
Swaab, F.
Swillens, S.

Tait, S.A.
Tashjian, A.H.
Tata, J.R.
Terenius, L.
Teschemacher, H.
Tixier-Vidal, A.
Touber, J.L.
Tsafriri, A.

Vale, W.W.
van der Gugten, A.A.
van der Molen, H.J.
van Obberghen, E.
Vanha-Perttula, T.
Verhoeven, G.
Vernon, R.G.
Vinson, G.P.
Visser, T.J.

Walker, A.
Wallis, M.
Weintraub, B.D.
Wieland, O.
Williams-Ashman, H.G.

Zapf, J.
Zor, U.
Zwilling, R.

0303-7207/84/$03.00 © 1984 Elsevier Scientific Publishers Ireland, Ltd.